SBIR/STTR Research Award
Development of a VesiVax TLR7 Formula as an Effective Adjuvant
Award amount
$2,999,352Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2024Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MOLECULAR EXPRESS, INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- R1JMHFESEKD5
- Solicitation number
- PHS-2024-1
- Topic code
- 128
Research abstract
The goal of this project is to develop the manufacturing processes of a highly immmunogenic TLR7 formulation, VesiVax ME-M-006. Development lots of VesiVax ME-M-006 will be produced, its equivalency and preliminary stability will be established. A quality system will be inititated for the manufacturing and product characterization proceesses.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Preclinical Development of a ME-1001, a Synthetic Lung Surfactant
- DESIGN AND ENGINEERING OF VESIVAX HIV IMMUNOGEN FORMULATIONS
- DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151.
- VesiVax Vaccine Formulation Against Neisseria gonorrhoeae
- Development of a VesiVax HIV Vaccine Formulation
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MRNA VACCINE DEVELOPMENT
- DEVELOPMENT OF COVALENTLY BOUND HYALURONIC ACID AS AN ADJUVANT FOR MULTIVALENT LYME DISEASE VACCINE
Research funding history
55 SBIR/STTR records share this UEI (1998–2024). Reported award amounts total $36,762,517. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense